iTeos Therapeutics, Inc. (ITOS)

Market Cap	486.15M
Revenue (ttm)	267.63M
Net Income (ttm)	96.65M
Shares Out	35.72M
EPS (ttm)	2.56
PE Ratio	5.32
Forward PE	12.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	320,325
Open	13.22
Previous Close	13.19
Day's Range	13.10 - 13.67
52-Week Range	12.52 - 35.64
Beta	1.42
Analysts	Buy
Price Target	44.63 (+227.92%)
Earnings Date	May 11, 2023

About ITOS

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2020
• Employees: 94
• Stock Exchange: NASDAQ
• Ticker Symbol: ITOS

Financial Performance

In 2022, ITOS's revenue was $267.63 million, a decrease of -22.38% compared to the previous year's $344.78 million. Earnings were $96.65 million, a decrease of -54.95%.

Analyst Forecast

According to 11 analysts, the average rating for ITOS stock is "Buy." The 12-month stock price forecast is $44.63, which is an increase of 227.92% from the latest price.

Price Target

$44.63

(227.92% upside)

Analyst Consensus: Buy